ForCast’s FC001 Granted Qualified Infectious Disease Product Designation

ForCast’s FC001 therapy to treat periprosthetic joint infection (PJI) has been granted Qualified Infectious Disease Product Designation.

PJI is a rare but serious complication of joint replacement surgery that can threaten the function of the joint and the life of the patient. In PJI, infecting bacteria adhere to the prosthesis, creating a protective biofilm that can be resistant to standard antibiotics taken orally.

ForCast’s FC001 is being developed to deliver a targeted antibiotic therapy directly into the infected joint.

The Qualified Infectious Disease Product Designation is designed to promote the development of new antifungal and antibacterial drugs. The designation offers incentives such as Fast Track designation, priority review, and additional market exclusivity given if the product receives FDA approval.

Related Topics